Novo Nordisk wins EU agency backing for new insulin (Reuters, 19 October 2012)

22 Oct 2012

The European Medicines Agency has recommended approval of the marketing application for Novo Nordisk's long-acting insulin Tresiba (insulin degludec).

Full article

The European Medicines Agency highlight that this is the first higher-strength insulin for treatment of patients with diabetes mellitus recommended for approval in the EU: EMA press release (19 October 2012)

Novo Nordisk wins EU agency backing for new insulin (Reuters, 19 October 2012)

Share this story

Top stories

Most read